Ownership and insider activity for Sanofi (SNY): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Price
| Price | $44.34 (closing price, October 30, 2026) |
| Market Cap | $106.9B |
| Exchange | NASDAQ |
| Country | FR |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 10.27B EUR | 10.31B EUR | 6.92B EUR | 9.74B EUR | 13.91B EUR | 10.10B EUR | 12.74B EUR | 8.71B EUR | 7.44B EUR | 7.66B EUR |
| Short-term Investments | 108.0M EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 486.0M EUR | 810.0M EUR |
| Receivables | 9.05B EUR | 8.68B EUR | 9.35B EUR | 10.08B EUR | 9.95B EUR | 9.79B EUR | 10.75B EUR | 11.04B EUR | 10.63B EUR | 11.05B EUR |
| Inventory | 6.89B EUR | 6.82B EUR | 7.48B EUR | 7.99B EUR | 8.35B EUR | 8.71B EUR | 8.96B EUR | 9.67B EUR | 9.43B EUR | 10.21B EUR |
| Total Current Assets | 26.69B EUR | 26.35B EUR | 24.58B EUR | 28.61B EUR | 33.70B EUR | 30.56B EUR | 34.03B EUR | 30.66B EUR | 42.59B EUR | 30.95B EUR |
| Property, Plant & Equipment | 10.02B EUR | 9.58B EUR | 9.65B EUR | 11.02B EUR | 10.56B EUR | 11.98B EUR | 11.68B EUR | 11.81B EUR | 11.60B EUR | 11.51B EUR |
| Goodwill | 40.29B EUR | 40.26B EUR | 44.23B EUR | 44.52B EUR | 44.36B EUR | 48.06B EUR | 49.89B EUR | 49.40B EUR | 43.38B EUR | 41.30B EUR |
| Intangible Assets | 10.88B EUR | 13.08B EUR | 21.89B EUR | 16.57B EUR | 18.34B EUR | 21.41B EUR | 21.64B EUR | 24.32B EUR | 22.63B EUR | 26.26B EUR |
| Total Assets | 104.67B EUR | 99.81B EUR | 111.41B EUR | 112.74B EUR | 114.41B EUR | 120.24B EUR | 126.72B EUR | 126.46B EUR | 132.80B EUR | 126.81B EUR |
| Accounts Payable | 4.30B EUR | 4.63B EUR | 5.04B EUR | 5.31B EUR | 5.29B EUR | 6.18B EUR | 6.81B EUR | 7.33B EUR | 7.55B EUR | 7.36B EUR |
| Short-term Debt | 1.76B EUR | 1.27B EUR | 2.63B EUR | 4.82B EUR | 3.00B EUR | 3.45B EUR | 4.45B EUR | 2.32B EUR | 4.21B EUR | 4.34B EUR |
| Total Current Liabilities | 16.43B EUR | 15.46B EUR | 17.38B EUR | 20.38B EUR | 19.25B EUR | 21.30B EUR | 23.96B EUR | 24.19B EUR | 29.16B EUR | 28.34B EUR |
| Long-term Debt | 16.78B EUR | 14.31B EUR | 21.99B EUR | 20.13B EUR | 19.75B EUR | 17.12B EUR | 14.86B EUR | 14.35B EUR | 11.79B EUR | 14.25B EUR |
| Total Liabilities | 46.95B EUR | 41.57B EUR | 52.37B EUR | 53.63B EUR | 51.16B EUR | 51.21B EUR | 51.57B EUR | 52.11B EUR | 54.94B EUR | 55.09B EUR |
| Retained Earnings | 51.48B EUR | 52.86B EUR | 53.11B EUR | 51.78B EUR | 60.15B EUR | 63.01B EUR | 66.73B EUR | 67.50B EUR | 0 | 0 |
| Total Equity | 57.55B EUR | 58.07B EUR | 58.88B EUR | 58.93B EUR | 63.11B EUR | 68.68B EUR | 74.78B EUR | 74.04B EUR | 77.51B EUR | 71.38B EUR |
| Total Debt | 18.58B EUR | 15.60B EUR | 24.64B EUR | 25.93B EUR | 23.68B EUR | 22.41B EUR | 21.21B EUR | 18.70B EUR | 17.91B EUR | 20.33B EUR |
| Net Debt | 8.20B EUR | 5.29B EUR | 17.71B EUR | 16.19B EUR | 9.76B EUR | 12.32B EUR | 8.48B EUR | 9.99B EUR | 9.98B EUR | 11.86B EUR |
| Working Capital | 10.25B EUR | 10.89B EUR | 7.20B EUR | 8.23B EUR | 14.46B EUR | 9.27B EUR | 10.06B EUR | 6.46B EUR | 13.43B EUR | 2.61B EUR |
Financial Health
| Debt / Equity | 0.34 |
| Current Ratio | 0.99 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.74 |
Profitability
| Return on Equity | 5.52% |
| Return on Invested Capital | 7.41% |
| Return on Assets | 3.07% |
| Gross Margin | 72.77% |
| Operating Margin | 20.58% |
| Net Margin | 8.09% |
Related companies: MRK · AMGN · GILD · LLY · AZN · NVS · NVO · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of SNY: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks